You are here: Industry Insights > PARP

News List

UT Southwestern finds crucial new molecular mechanisms and biomarkers in ovarian cancer firstwordpharma
August 02, 2021
UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.
Researchers identify new drug class with potential in BRCA-mutated tumours pharmatimes
June 21, 2021
Researchers from the The Institute of Cancer Research, London and Artios have identified a new class of drugs – POLQ inhibitors – which could have potential for patients with BRCA-mutated tumours.
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer pharmaceutical-business-review
June 17, 2020
Clovis Oncology announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP) ...
AstraZeneca, Merck's Lynparza plows ahead in ovarian cancer with $1B-plus approval, phase 3 data fiercepharma
December 24, 2018
The year may be winding down, but AstraZeneca and Merck’s Lynparza sure isn’t. It picked up a blockbuster new approval late Wednesday and followed up the act by posting positive phase 3 data Thursday morning.
Tesaro's deal struggles? They're actually a good omen for Clovis: analyst fiercepharma
December 20, 2018
PARP drugmaker Tesaro may have had a tough time finding a buyer in GlaxoSmithKline. But that doesn’t mean rival Clovis won’t be able to land its own, one analyst says.
GlaxoSmithKline to buy Tesaro for $5.1 billion, gaining PARP inhibitor Zejula firstwordpharma
December 03, 2018
GlaxoSmithKline announced Monday an agreement to acquire Tesaro for around $5.1 billion in cash, gaining the latter's oral PARP inhibitor Zejula (niraparib). GlaxoSmithKline CEO Emma Walmsley said the deal "will strengthen our pharmaceuticals business by
Pfizer, Merck KGaA's Bavencio flunks ovarian cancer trial fiercepharma
November 20, 2018
Mark another tally for Pfizer and Merck KGaA’s Bavencio in the “loss” column.
Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting pharmatimes
July 16, 2018
European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
Clovis’ PARP drug gets new US ovarian cancer use pharmaphorum
April 12, 2018
The FDA has granted Clovis Oncology’s rucaparib a new use in ovarian cancer, approving the PARP inhibitor as a maintenance therapy for women with recurrent disease.
AstraZeneca's Lynparza ups the ante at the PARP table with FDA's speedy breast cancer review fiercepharma
October 19, 2017
The agency Wednesday accepted the British drugmaker’s approval application and granted the medication its “priority review” tag.

Previous page 1 2 Next page